首款靶向RNA的小分子药物发展态势良好。 - Suppr

Suppr

超能文献

First small-molecule drug targeting RNA gains momentum.

作者信息

Sheridan Cormac

机构信息

, Dublin, Ireland.

出版信息

Nat Biotechnol. 2021 Jan;39(1):6-8. doi: 10.1038/s41587-020-00788-1.

DOI:10.1038/s41587-020-00788-1

PMID:33432225

Abstract

摘要

相似文献

First small-molecule drug targeting RNA gains momentum.

Nat Biotechnol. 2021 Jan;39(1):6-8. doi: 10.1038/s41587-020-00788-1.

First Oral Drug Approved for Spinal Muscular Atrophy.

Am J Nurs. 2020 Dec;120(12):22-23. doi: 10.1097/01.NAJ.0000724220.73804.9d.

In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.

Med Lett Drugs Ther. 2021 Jul 26;63(1629):e1-e2.

Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).

J Med Chem. 2018 Aug 9;61(15):6501-6517. doi: 10.1021/acs.jmedchem.8b00741. Epub 2018 Jul 25.

Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy.

Ann Clin Transl Neurol. 2021 Jan;8(1):54-65. doi: 10.1002/acn3.51239. Epub 2020 Nov 24.

A severely affected adult type 2 spinal muscular atrophy patient treated with risdiplam.

Neurol Sci. 2023 Apr;44(4):1449-1450. doi: 10.1007/s10072-022-06539-1. Epub 2022 Dec 6.

Rewriting the (tran)script: Application to spinal muscular atrophy.

Prog Med Chem. 2019;58:119-156. doi: 10.1016/bs.pmch.2018.12.003. Epub 2019 Feb 1.

Advances in the Therapy of Spinal Muscular Atrophy.

J Pediatr. 2021 Sep;236:13-20.e1. doi: 10.1016/j.jpeds.2021.06.033. Epub 2021 Jun 29.

Target-Directed Approaches for Screening Small Molecules against RNA Targets.

SLAS Discov. 2020 Sep;25(8):869-894. doi: 10.1177/2472555220922802. Epub 2020 May 18.

The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.

Neuromuscul Disord. 2019 Jan;29(1):21-29. doi: 10.1016/j.nmd.2018.10.001. Epub 2018 Oct 30.

引用本文的文献

Identification of p38 MAPK inhibition as a neuroprotective strategy for combinatorial SMA therapy.

EMBO Mol Med. 2025 Sep 8. doi: 10.1038/s44321-025-00303-6.

Exploiting functional regions in the viral RNA genome as druggable entities.

Elife. 2025 Jul 2;13:RP103923. doi: 10.7554/eLife.103923.

Designing Reversible Photoswitching Azobenzene-Modified Nucleotide for Controlling Biological Function.

J Am Chem Soc. 2025 Jun 25;147(25):21638-21648. doi: 10.1021/jacs.5c03252. Epub 2025 Jun 13.

Path-Based Nonequilibrium Binding Free Energy Estimation, from Protein-Ligand to RNA-Ligand Binding.

J Chem Inf Model. 2025 Jun 23;65(12):6057-6072. doi: 10.1021/acs.jcim.5c00452. Epub 2025 Jun 6.

Harnessing Computational Approaches for RNA-Targeted Drug Discovery.

RNA Nanomed. 2024 Dec;1(1):1-15. doi: 10.59566/isrnn.2024.0101001.

Three- and four-stranded nucleic acid structures and their ligands.

RSC Chem Biol. 2025 Feb 19;6(4):466-491. doi: 10.1039/d4cb00287c. eCollection 2025 Apr 2.

RNAbpFlow: Base pair-augmented SE(3)-flow matching for conditional RNA 3D structure generation.

bioRxiv. 2025 Jan 26:2025.01.24.634669. doi: 10.1101/2025.01.24.634669.

Targeting RNA splicing modulation: new perspectives for anticancer strategy?

J Exp Clin Cancer Res. 2025 Jan 30;44(1):32. doi: 10.1186/s13046-025-03279-w.

Accurate RNA 3D structure prediction using a language model-based deep learning approach.

Nat Methods. 2024 Dec;21(12):2287-2298. doi: 10.1038/s41592-024-02487-0. Epub 2024 Nov 21.

sChemNET: a deep learning framework for predicting small molecules targeting microRNA function.

Nat Commun. 2024 Oct 23;15(1):9149. doi: 10.1038/s41467-024-49813-w.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验